DATA SHEET

For research use only. Not for use in humans.

Reagent: J-Lat Full Length Cells (10.6)

Catalog Number: ARP-9849

Lot Number: 190416

Release Category: C

Provided: Each vial of ARP-9849 contains approximately 3 × 10^6 cells in 0.8 mL of Gibco Recovery Cell Culture Freezing Medium. Post-thaw viability was 83%.

Cell Type: Human T cell lymphoblast

Propagation Medium: The recommended propagation medium is 90% RPMI 1640 medium supplemented with 10% fetal bovine serum and 2 mM Glutamax.

Freeze Medium: The recommended freeze medium is Gibco Recovery Cell Culture Freezing Medium.

Growth Characteristics: ARP-9849 grows in suspension with a small, spherical morphology, usually singly but some clumping has been noted. There are no special requirements for thawing and reestablishing the culture. Cultures should be split at 1:3 at 1 × 10^6 cells per mL.

Sterility: Tests for bacteria, fungi and mycoplasma were negative.

Description: ARP-9849 is a Jurkat-based cell line containing a full-length integrated human immunodeficiency virus 1 (HIV-1) genome that expresses GFP upon activation. The genome generates incomplete virions due to a frameshift in *env* gene.

Special Characteristics: ARP-9849 was generated by infecting the Jurkat cells with the packaged retroviral construct HIV-R7/E-/GFP, which is a full-length HIV-1 genome with a non-functional *env* due to a frameshift, and GFP in place of the *nef* gene. The full-length constructs secrete incomplete viral particles (capsids). ARP-9849 expresses low to undetectable levels of GFP under basal conditions and is suited to study HIV latency and reactivation.

The clones in this series are: 6.3 (ARP-9846), 8.4 (ARP-9847), 9.2 (ARP-9848), 10.6 (ARP-9849), and 15.4 (ARP-9850).

Please see Table I in the reference publication for differences between these clones in GFP and p24 expression upon stimulation with TNF-α.

Recommended Storage: Keep at -100°C or colder, preferably in the vapor phase of a liquid nitrogen freezer.

Contributor: Dr. Eric Verdin

Reference: Jordan, A., B. Bisgrove and E. Verdin. “HIV Reproducibly Establishes a Latent Infection after Acute Infection of T Cells in vitro.” EMBO J. 22 8 (2003): 1868-1877. PubMed: 12682019.

Citation: Acknowledgment for publications should read “The following reagent was obtained through the NIH HIV Reagent Program, Division of AIDS, NIAID, NIH: J-Lat Full Length Cells (10.6), ARP-9849, contributed by Dr. Eric Verdin.” Also include the references cited in any publication.

Biosafety Level: 2 Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 6th ed. Washington, DC: U.S. Government Printing Office, 2020.

NIH HIV Reagent Program
www.hivreagentprogram.org

E-mail: contact@HIVReagentProgram.org
Tel: 888-487-0727
Fax: 703-365-2898

Disclaimers:

You are authorized to use this product for research use only. It is not intended for use in humans.

Use of this product is subject to the terms and conditions of the NIH HIV Reagent Program Material Transfer Agreement (MTA). The MTA is available on our Web site at www.hivreagentprogram.org.

While the NIH HIV Reagent Program uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to the NIH HIV Reagent Program are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before the first commercial sale.

Note:

These cells and methods of use are covered by US Patents 7,232,685 and 7,544,467.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact the J. David Gladstone Institutes, Email: veronica.viray@gladstone.ucsf.edu, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.

ATCC® is a trademark of the American Type Culture Collection.

Support Provided by NIAID

NIH HIV Reagent Program
www.hivreagentprogram.org

E-mail: contact@HIVReagentProgram.org
Tel: 888-487-0727
Fax: 703-365-2898